Harmony Biosciences Inc. (HRMY)
NASDAQ: HRMY
· Real-Time Price · USD
35.99
-0.31 (-0.85%)
At close: Sep 05, 2025, 3:59 PM
35.50
-1.36%
After-hours: Sep 05, 2025, 05:34 PM EDT
-0.85% (1D)
| Bid | 35.5 |
| Market Cap | 2.07B |
| Revenue (ttm) | 772.53M |
| Net Income (ttm) | 180.9M |
| EPS (ttm) | 3.1 |
| PE Ratio (ttm) | 11.61 |
| Forward PE | 9.65 |
| Analyst | Buy |
| Ask | 37 |
| Volume | 710,978 |
| Avg. Volume (20D) | 596,124 |
| Open | 36.34 |
| Previous Close | 36.30 |
| Day's Range | 35.74 - 36.57 |
| 52-Week Range | 26.47 - 41.61 |
| Beta | 0.84 |
About HRMY
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HRMY
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HRMY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Harmony Biosciences Inc. is scheduled to release its earnings on
Oct 28, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.69%
Harmony Biosciences Holdings shares are trading lo...
Unlock content with
Pro Subscription
6 months ago
-9.64%
Harmony Biosciences shares are trading lower after the company received a refusal to file letter from the FDA for Pitolisant.
1 month ago · seekingalpha.com
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call TranscriptHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Adam Zaeske - Executive VP & Chief Commercial Officer Brennan Doyle - ...
